Nintedanib

July 20, 2017July 20, 2017

Samumed Completes Phase 1 Study of Potential IPF Treatment with Positive Results

Samumed has successfully completed a Phase 1 clinical trial in healthy individuals to evaluating a potential therapy — a nebulized inhalation solution called SM04646 — that treats idiopathic pulmonary fibrosis (IPF). The positive ... Read more

July 17, 2017July 17, 2017

Esbriet, Ofev Remain the Most Reliable Therapies for Idiopathic Pulmonary Fibrosis, Comparison Study Shows

Idiopathic Pulmonary Fibrosis, News

The first two approved therapies for idiopathic pulmonary fibrosis (IPF), Genentech’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib), are still the most reliable treatments among several approved and experimental therapies, according to a ... Read more

May 26, 2017May 26, 2017

Ofev Doubles the Chance of Improving or Stabilizing IPF, Studies Find

Idiopathic Pulmonary Fibrosis, News

Idiopathic pulmonary fibrosis (IPF) patients treated with Ofev (nintedanib) are twice as likely to improve or see their disease stabilize than untreated patients, according to a pool of data from ... Read more

April 20, 2017April 20, 2017

Boehringer Ingelheim Phase 3 Trial Evaluates Ofev in Patients with Progressive Fibrosing Interstitial Lung Disease

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim Pharmaceuticals has enrolled the first patient in its progressive fibrosing interstitial lung disease (PF-ILD) clinical trial, which will investigate the effectiveness and safety of Ofev (nintedanib) in a ... Read more

March 28, 2017March 28, 2017

Phase 3 Study of Ofev as Treatment for Progressive Fibrosing Lung Diseases Now Enrolling Patients

Idiopathic Pulmonary Fibrosis, News

The first patient has been enrolled in Boehringer Ingelheim’s Phase 3 clinical trial investigating the effectiveness and safety of Ofev (nintedanib) in progressive fibrosing interstitial lung diseases (PF-ILD). ILD encompasses a ... Read more

March 23, 2017March 23, 2017

New Research Reveals How IPF Treatments Ofev and Esbriet Work

Idiopathic Pulmonary Fibrosis, News

Researchers from Germany have identified how Ofev (nintedanib) and Esbriet (pirfenidone) work — two FDA-approved drugs for the treatment of idiopathic pulmonary fibrosis (IPF). The study, titled “A Novel Antifibrotic Mechanism ... Read more

October 25, 2016October 25, 2016

Phase 3 Trial Data Supports Effectiveness of Ofev in Treating IPF, Regardless of Disease Severity

Idiopathic Pulmonary Fibrosis, News

Analyses of data from two Phase 3 INPULSIS trials support using Ofev (nintedanib) for patients with idiopathic pulmonary fibrosis (IPF). The trials included IPF patients at different disease stages, and revealed that Ofev treatment is ... Read more

September 14, 2016September 14, 2016

Boehringer Reports Long-term Positive Effects of IPF Therapy Ofev

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim recently shared positive data from a clinical trial evaluating long-term treatment with Ofev (nintedanib) in idiopathic pulmonary fibrosis (IPF) patients. The interim findings from the INPULSIS-ON extension trial were ... Read more

August 2, 2016August 2, 2016

Trial Launches to Evaluate Ofev on IPF-Predicting Biomarkers

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim Pharmaceuticals announced the launch of a new clinical trial to investigate the effects of Ofev (nintedanib) on certain blood biomarkers that might help identify fibrosis and loss of lung function ... Read more

June 28, 2016June 28, 2016

Analysis Shows IPF Treatment OFEV (Nintedanib) Effective in Test, Broader Criteria

Idiopathic Pulmonary Fibrosis, News

The latest analysis of Inpulsis clinical trials demonstrated that Ofev (nintedanib) for idiopathic pulmonary fibrosis slows the disease progression and that treatment results are similar using broader diagnostic criteria than required. The data was ... Read more